Financial Calendar

13 March 2025 FY 2024 financial results
13 May 2025 Q1 2025 financial results
11 June 2025 Annual shareholders' meeting
06 August 2025 H1 2025 financial results
13 November 2025 Q3 2025 financial results
Past Events
06 November 2024 Q3 2024 financial results
06 August 2024 Q2 2024 financial results
06 August 2024 H1 2024 financial results
12 June 2024 Annual shareholders’ meeting
14 May 2024 Q1 2024 financial results
02 April 2024 2023 annual report
05 March 2024 FY 2023 financial results
08 November 2023 Q3 2023 financial results
Webcast
https://edge.media-server.com/mmc/p/5tvtajxd/
08 August 2023 H1 2023 financial results
14 June 2023 Annual shareholders’ meeting
Upcoming Events

Financial Downloads

SEC Filings

Special Reports

Special auditor report – Articles 7:180 juncto 7:179 and 7:191 CCA (2024 Warrants Plan)

Special Reports
Download (FR)

Special auditor report - Article 7:97 CCA (Capital increase - related party transaction)

Special Reports
Download FR

Advice by committee of independent directors - Article 7:97 CCA (Capital increase - related party transaction)

Special Reports
Download FR Download ENG

Special auditor report - Articles 7:179, 7:191 and 7:193 CCA (Capital increase - cancellation of preferential subscription right)

Special Reports
Download FR

Special board report - Articles 7:179, 7:191 and 7:193 CCA (Capital increase - cancellation of preferential subscription right)

Special Reports
Download FR Download ENG

Special auditor report - Articles 7:198 juncto 7:179, 7:191 and 7:193 CCA (Private placement)

Special Reports
Download (FR)

Special auditor report – Articles 7:180 juncto 7:179 and 7:191 CCA (2022 Warrants Plan)

Special Reports
Download (FR)

All rights reserved © 2021 Nyxoah SA. All content on this presentation, including the texts, trademarks, service marks, logos, illustrations, photos, graphics, design etc., are the property of Nyxoah SA. Nyxoah SA. owns all rights with respect to any of their trademarks, service marks, logos, and copyrighted works appearing on this presentation. Patented and design protected technology. Device not for sale in U.S. The Genio® system by Nyxoah is intended to be used for patients who suffer from moderate to severe Obstructive Sleep Apnea (AHI of 15 to 65), have not tolerated, failed or refused PAP therapy and are not significantly overweight. Reviewed and approved: February 2020

Privacy Notice
Cookie Policy
 Cookie Settings
bubble
bubble
bubble
bubble
bubble